EClinicalMedicine
Elinzanetant’s safety profile appeared favorable in women
Over 12 weeks, new or worsening health problems occurred in 50.8% of women taking elinzanetant and 43.2% taking placebo.Over 12 weeks, new or worsening health problems occurred in 50.8% of women taking elinzanetant and 43.2% taking placebo.

Meta-analysis · 1,519 peopleElinzanetant
Who was studied1,519 postmenopausal women with moderate-to-severe vasomotor symptoms, 12-week
What changedAdverse events were more common with elinzanetant: 50·8% versus 43·2% with placebo over 12 weeks
The catchExposure-adjusted rates assume constant risk over time, potentially masking early-onset or transient harms

